Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES
Print Format
Change Text Size:

BRIEF-Horizon Therapeutics Says Received European Commission Approval Of Uplizna

BY Reuters
— 1:05 AM ET 05/02/2022

May 2 (Reuters) - Horizon Therapeutics PLC (HZNP):

* HORIZON THERAPEUTICS PLC RECEIVES EUROPEAN COMMISSION (EC) APPROVAL OF UPLIZNA® (INEBILIZUMAB) FOR THE TREATMENT OF ADULTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

* HORIZON THERAPEUTICS (HZNP) - EC APPROVAL SUPPORTED BY RESULTS FROM N-MOMEMTUM, SHOWED 87.6% OF AQP4-IGG+ NMOSD PATIENTS ON UPLIZNA WERE ATTACK FREE FOR 28 WEEKS Source text for Eikon: Further company coverage:

Copyright © Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

More HZNP News
Copyright 1998–2022 FMR LLC. 
All rights reserved. 
Close